CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance

Highly purified CD38+ and CD38− sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin

“…Moreover, the expression of the CD38 antigen defines a sub-population of CLL cells with a distinct transcriptional profile that may be the cause or effect of an increase in cellular activation. 35,36 A number of recent studies have demonstrated an important role for VEGF in CLL 23-25,37-39 and one described an association between VEGF and CD38. 26 Directed by the differential transcription of VEGF revealed in our gene expression profiling data, we confirmed that CD38 þ CLL cells contained more VEGF protein than their CD38 À counterparts derived from the same patient.…”

The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia

“…31 CD49d is a cell-surface antigen that functions as part of a celladhesion molecule. High expression of CD49d predicts for decreased survival outcomes in patients with CLL, 32 and studies are ongoing to further evaluate the prognostic value of this marker and to determine the optimal cut-off levels for its expression.…”

The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells

“…6,30 This series was employed to extend our previous observations on correlated expression and clinical impact of CD49d and CD38 in CLL. 6,31,32 For CD49d and CD38 simultaneous detection, a combination of anti-CD5-FITC, anti-CD49d-PE, anti-CD19-PerCP and anti-CD38-APC monoclonal antibodies (mAbs; Becton Dickinson, San Jose, CA, USA) was used. A CLL case was judged CD49d þ and/or CD38 þ when the marker was expressed in at least 30% of the CD5 þ CD19 þ CLL cell population, as described.…”